MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Stratipath and Roche Collaborate to Broaden Access to AI-Driven Precision Diagnostics

NextEdge Admin

09 Sep 2024

1 min 28 sec

Stratipath, a global leader in AI-powered precision diagnostics, has announced a collaboration with Roche, the world’s largest biotechnology company and a leader in in-vitro diagnostics. Through this non-exclusive partnership, Roche will distribute Stratipath’s AI-based solution, Stratipath Breast, integrated into the navify® Digital Pathology platform. This allows Roche customers to perform prognostic risk profiling for breast cancer directly within the platform.

Stratipath Breast, the first EU-compliant AI solution for breast cancer risk stratification, analyzes digitized histopathology images to identify patients at higher risk of disease progression. Unlike conventional molecular tests, AI-based diagnostics offer faster turnaround times, new insights at diagnosis, and lower costs, increasing accessibility for more patients.

Fredrik Wetterhall, CEO of Stratipath, highlights how this integration streamlines lab processes while providing rapid access to prognostic insights, benefiting breast cancer patients globally. The collaboration underscores a shared commitment to enhancing breast cancer care through AI and digital pathology.